A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers.

Youngberg, Stephen; Brandt, Erin; Barve, Avantika; Machineni, Surendra; Jones, Christopher T; Dabovic, Kristina; Jones, Catherine L; Colvin, Richard A

Youngberg, Stephen; Brandt, Erin; Barve, Avantika; Machineni, Surendra; Jones, Christopher T; Dabovic, Kristina; Jones, Catherine L; Colvin, Richard A.

Afiliación

Youngberg S; Celerion, Lincoln, NE, USA.
Brandt E; Celerion, Lincoln, NE, USA.
Barve A; Novartis Institutes for BioMedical Research, East Hanover, NJ, USA.
Machineni S; Novartis Healthcare Private Limited, Hyderabad, India.
Jones CT; Novartis Institutes for BioMedical Research, Emeryville, CA, USA.
Dabovic K; Novartis Institutes for BioMedical Research, East Hanover, NJ, USA.
Jones CL; Novartis Institutes for BioMedical Research, Emeryville, CA, USA.
Colvin RA; Novartis Institutes for BioMedical Research, Cambridge, MA, USA.

J Drug Assess ; 7(1): 66-74, 2018.

Article en En | MEDLINE | ID: mdl-30370176

Palabras clave

BZF961; First-in-human; protease inhibitor; ritonavir

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: J Drug Assess Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google